Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen
O
O
Department of Clinical Neuroscience, University of Götenborg, Sweden.
Lycke
J
J
Tollesson
P O
PO
Svenningsson
A
A
Runmarker
B
B
Linde
A S
AS
Aström
M
M
Gjörstrup
P
P
Ekholm
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D006912:Hydroxyquinolines; C045282:roquinimex